| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
LEI-110 targets the HRASLS family of thiol hydrolases, which includes PLA2G16 (adipose phospholipase A2), HRASLS2 (HRas-like suppressor 2), RARRES3 (retinoic acid receptor responder protein 3), and iNAT (calcium-independent N-acyltransferase). These enzymes are involved in lipid metabolism, including the hydrolysis of phospholipids and the transfer of acyl groups. PLA2G16 is a phospholipase that hydrolyzes the sn-2 position of phospholipids, releasing fatty acids and lysophospholipids. LEI-110 inhibits PLA2G16 with a Ki of 20 nM and an IC50 of 100 nM. By inhibiting these enzymes, LEI-110 modulates lipid signaling pathways and cellular metabolism.
|
|---|---|
| ln Vitro |
In vitro, LEI-110 demonstrates potent inhibition of its target enzymes with IC50 values in the low nanomolar to low micromolar range. The compound inhibits PLA2G16 with an IC50 of 100 nM, HRASLS2 with an IC50 of 158 nM, RARRES3 with an IC50 of 158 nM, and iNAT with an IC50 of 25 nM. LEI-110 is cell-penetrating, allowing it to access its intracellular targets. The compound's selectivity for the HRASLS family over other enzymes makes it a valuable tool for studying the specific roles of these enzymes in cellular processes.
|
| ln Vivo |
In vivo data for LEI-110 is limited in the available literature. The compound is primarily used as a research tool for in vitro studies of lipid metabolism and cell signaling. LEI-110's ability to inhibit PLA2G16, HRASLS2, RARRES3, and iNAT suggests potential applications in studying obesity, inflammation, and cancer, but specific in vivo efficacy data has not been extensively reported.
|
| Enzyme Assay |
LEI-110's inhibition of its target enzymes is assessed using biochemical enzyme assays. Recombinant PLA2G16, HRASLS2, RARRES3, and iNAT are incubated with the test compound and the appropriate substrate; enzymatic activity is measured by detecting the product of the enzymatic reaction (e.g., by HPLC, mass spectrometry, or fluorometry). IC50 values are calculated from dose-response curves. These assays provide quantitative information on the potency and selectivity of LEI-110.
|
| Cell Assay |
LEI-110 is tested on cultured cells to assess its effects on lipid metabolism and cell signaling. Cells are treated with varying concentrations of LEI-110; lipid levels are measured by lipidomics or thin-layer chromatography; signaling pathways are assessed by Western blot for phosphorylated proteins; cell proliferation is assessed by MTT or CellTiter-Glo assays. These cell-based assays demonstrate the mechanism of action and cellular activity of LEI-110.
|
| Animal Protocol |
Animal studies for LEI-110 are limited in the available literature. The compound has not been extensively evaluated in vivo, and specific animal models, dosing regimens, and efficacy endpoints have not been reported. LEI-110 is primarily used as a research tool for in vitro studies. Further studies are needed to characterize the in vivo activity and therapeutic potential of LEI-110.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for LEI-110 is not available in the literature. The compound is used primarily in research settings for in vitro studies. As a cell-penetrating compound, LEI-110 is expected to have properties suitable for cellular penetration, but its absorption, distribution, metabolism, and excretion have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for LEI-110 is not available in the literature. The compound is used in research settings and has not been evaluated for clinical safety. As an inhibitor of lipid-metabolizing enzymes, LEI-110 may have effects on normal cellular metabolism, and its toxicity profile would need to be characterized in future studies.
|
| Additional Infomation |
LEI-110 is a potent, selective, cell-penetrating pan-inhibitor of the HRASLS family of thiol hydrolases, including PLA2G16 (Ki = 20 nM), HRASLS2, RARRES3, and iNAT. The compound has pIC50 values of 7.0 for PLA2G16, 6.8 for HRASLS2, 6.8 for RARRES3, and 7.6 for iNAT. LEI-110 is used as a research tool for studying the roles of these enzymes in lipid metabolism, cell signaling, obesity, inflammation, and cancer. The compound is not approved as a therapeutic agent and is used for research purposes only.
|
| Molecular Formula |
C25H23F3N2O3
|
|---|---|
| Molecular Weight |
456.456937074661
|
| Exact Mass |
456.166
|
| CAS # |
2313525-90-3
|
| PubChem CID |
156013201
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
33
|
| Complexity |
615
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CCCC(=O)C(=O)NCCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(F)(F)F
|
| InChi Key |
DZHZISUSQMPBJQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H23F3N2O3/c26-25(27,28)20-11-14-23(30-17-20)33-21-12-9-19(10-13-21)15-16-29-24(32)22(31)8-4-7-18-5-2-1-3-6-18/h1-3,5-6,9-14,17H,4,7-8,15-16H2,(H,29,32)
|
| Chemical Name |
2-oxo-5-phenyl-N-[2-[4-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]ethyl]pentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~219.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1908 mL | 10.9539 mL | 21.9077 mL | |
| 5 mM | 0.4382 mL | 2.1908 mL | 4.3815 mL | |
| 10 mM | 0.2191 mL | 1.0954 mL | 2.1908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
